Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Oct;204(4):701-706.
doi: 10.1097/JU.0000000000001088. Epub 2020 Apr 28.

Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study

Michael A Liss  1 , Lisa F Newcomb  2 , Yingye Zheng  3 , Michael P Garcia  3 , Christopher P Filson  4 , Hilary Boyer  2 , James D Brooks  5 , Peter R Carroll  6 , Matthew R Cooperberg  6 , William J Ellis  2 , Martin E Gleave  7 , Frances M Martin  8 , Todd Morgan  9 , Peter S Nelson  2 , Andrew A Wagner  10 , Ian M Thompson Jr  1   11 , Daniel W Lin  2
Affiliations
Multicenter Study

Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study

Michael A Liss et al. J Urol. 2020 Oct.

Abstract

Purpose: We investigated the ability of prostate magnetic resonance imaging to detect Gleason Grade Group 2 or greater cancer in a standardized, multi-institutional active surveillance cohort.

Materials and methods: We evaluated men enrolled in Canary Prostate Active Surveillance Study with Gleason Grade Group less than 2 and who underwent biopsy within 12 months of multiparametric magnetic resonance imaging. Our primary outcome was biopsy reclassification to Gleason Grade Group 2 or greater. We evaluated the performance of magnetic resonance imaging PI-RADS® score and clinical factors. Multivariable logistic regression models were fit with magnetic resonance imaging and clinical factors and used to perform receiver operating curve analyses.

Results: There were 361 participants with 395 prostate magnetic resonance imaging studies with a median followup of 4.1 (IQR 2.0-7.6) years. Overall 108 (27%) biopsies showed reclassification. Defining positive magnetic resonance imaging as PI-RADS 3-5, the negative predictive value and positive predictive value for detecting Gleason Grade Group 2 or greater cancer was 83% (95% CI 76-90) and 31% (95% CI 26-37), respectively. PI-RADS was significantly associated with reclassification (PI-RADS 5 vs 1 and 2 OR 2.71, 95% CI 1.21-6.17, p=0.016) in a multivariable model but did not improve upon a model with only clinical factors (AUC 0.768 vs 0.762). In 194 fusion biopsies higher grade cancer was found in targeted cores in 21 (11%) instances, while 25 (13%) had higher grade cancer in the systematic cores.

Conclusions: This study adds the largest cohort data to the body of literature for magnetic resonance imaging in active surveillance, recommending systematic biopsy in patients with negative magnetic resonance imaging and the inclusion of systematic biopsy in patients with positive magnetic resonance imaging.

Keywords: magnetic resonance imaging; prostatic neoplasms.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None

Figures

Figure 1.
Figure 1.
Receiver Operating Characteristic curves for prediction of reclassification.
See this image and copyright information in PMC

References

    1. Mohler JL, Antonarakis ES, Armstrong AJ et al.: Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 17: 479, 2019 - PubMed
    1. Bekelman JE, Rumble RB, Chen RC et al.: Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol: JCO1800606, 2018 - PubMed
    1. Mottet N, Bellmunt J, Bolla M et al.: EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol, 71: 618, 2017 - PubMed
    1. Hamdy FC, Donovan JL, Lane JA et al.: 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med, 375: 1415, 2016 - PubMed
    1. Loeb S, Vellekoop A, Ahmed HU et al.: Systematic review of complications of prostate biopsy. Eur Urol, 64: 876, 2013 - PubMed

Publication types